Welcome to our dedicated page for RenovoRx news (Ticker: RNXT), a resource for investors and traders seeking the latest updates and insights on RenovoRx stock.
RenovoRx, Inc. (RNXT) is a medical device and biopharmaceutical company based in Silicon Valley, California. The company focuses on developing innovative solutions for targeted delivery of fluids, including diagnostic and therapeutic agents to specific locations in the peripheral vascular system. With FDA clearance for their flagship product, RenovoCath™ RC120, RenovoRx is introducing this cutting-edge technology to the clinical market.
RenovoRx's proprietary platform, Trans-Arterial Micro-Perfusion (TAMP), aims to revolutionize cancer treatment by ensuring precise therapeutic delivery directly to the tumor site. This targeted approach is designed to reduce the toxicities commonly associated with systemic intravenous therapy, potentially improving therapeutic outcomes for cancer patients.
The company is driven by a highly motivated team with extensive experience in the medical field and supported by a robust medical advisory board and a distinguished board of directors. RenovoRx's commitment to innovation and patient care has positioned it as a leader in the area of targeted therapeutic delivery.
For more information or inquiries, please contact RenovoRx at info@renovorx.com.
RenovoRx, Inc. (Nasdaq: RNXT) announced a definitive agreement with an institutional investor to sell 1,557,632 shares of its common stock at $3.21 per share in a registered direct offering. The expected closing date is around April 3, 2023. Concurrently, the Company will issue warrants for an additional 1,947,040 shares at the same exercise price, with a term of five and a half years. Gross proceeds are anticipated to be approximately $5 million, aimed at working capital and general corporate purposes. Roth Capital Partners is the exclusive placement agent for this offering.
RenovoRx (NASDAQ: RNXT) announced promising interim data from its Phase III TIGeR-PaC trial for the RenovoGem therapy targeting pancreatic cancer. The results show a significant 6-month median overall survival benefit of 16 months for RenovoGem patients, compared to 10 months for those on standard IV chemotherapy. Notably, RenovoGem patients experienced over a 65% reduction in side effects like nausea and fatigue. These findings support discussions with the FDA to expedite further development. The second interim analysis is anticipated in mid-2024.
RenovoRx, Inc. (Nasdaq: RNXT) announced promising interim results from the Phase III TIGeR-PaC clinical trial for its product candidate, RenovoGem, aimed at treating locally advanced pancreatic cancer (LAPC).
The interim analysis indicates a 6-month increase in median overall survival in the RenovoGem group (16 months) compared to standard care (10 months). The trial is randomized, with 114 patients expected, and the current analysis included 45 patients. The Data Monitoring Committee recommends continuing the trial, with full data to be presented at the AACR Annual Meeting on April 17, 2023.
RenovoRx (Nasdaq: RNXT) reports financial results for 2022 and updates on its Phase III TIGeR-PaC clinical trial for localized pancreatic cancer treatment. The company has randomized 47 out of 114 patients, triggering its first interim analysis after recording 26 events (deaths). RenovoRx anticipates releasing the interim analysis results soon. Financially, cash and equivalents were $6.4 million at year-end, with total assets of $7.3 million against liabilities of $1.1 million. The company's net loss was $9.9 million, with a loss per share of ($1.09). Operating expenses increased to $10 million, driven by R&D and admin costs.
RenovoRx, a biopharmaceutical company focused on localized cancer treatment, announced CEO Shaun Bagai will present at the 35th Annual Roth Conference from March 12-14, 2023, in Dana Point, California. Bagai will discuss the company's lead product candidate, RenovoGem™, which aims to disrupt standard chemotherapy with targeted intra-arterial delivery using the proprietary RenovoTAMP® platform. The pivotal Phase III TIGeR-PaC clinical trial for RenovoGem is ongoing, with the first interim analysis expected soon. RenovoRx also plans to investigate RenovoGem for extrahepatic cholangiocarcinoma in 2023.
RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company, announced that CEO Shaun Bagai will virtually present at the Sequire Biotechnology Conference on February 2, 2023, at 4 p.m. (ET). The presentation will focus on RenovoRx's innovative RenovoTAMP® therapy platform, which aims to transform cancer treatment by delivering localized chemotherapy directly to solid tumors, improving patients' quality of life. Bagai will also discuss the ongoing Phase III TIGeR-PaC clinical trial targeting locally advanced pancreatic cancer, with the first interim analysis expected soon. The event is open to the public for registration.
RenovoRx, Inc. (Nasdaq: RNXT) announced initial results from a pharmacokinetic substudy within the phase III TIGeR-PaC clinical trial at the 2023 ASCO GI Cancers Symposium. This trial evaluates the intra-arterial administration of gemcitabine for treating Locally Advanced Pancreatic Cancer (LAPC) using the RenovoTAMP platform. Preliminary findings indicate that the RenovoTAMP method may reduce systemic drug exposure by over 50%, potentially minimizing side effects while enhancing local chemotherapy delivery. Three additional supportive abstracts will also be presented, advancing the understanding of pancreatic cancer treatment.
RenovoRx, Inc. (NASDAQ: RNXT) announced the issuance of US patent number 11,541,211 on January 3, 2023, covering methods for treating cholangiocarcinoma through targeted delivery of therapeutic agents. This patent is their eighth in the US, contributing to a robust intellectual property portfolio that includes 8 US method and device patents, one EU delivery system patent, and several pending patents globally. Additionally, the patent strengthens the seven years of market exclusivity RenovoRx holds for its lead product candidate, RenovoGem™, under FDA's Orphan Drug designation.
RenovoRx, Inc. (Nasdaq: RNXT) announced the acceptance of four clinical data abstracts supporting its lead oncology candidate, RenovoGem, at the 2023 ASCO Gastrointestinal Cancers Symposium, scheduled for January 19-21, 2023, in San Francisco, California.
RenovoGem, evaluated in a Phase III trial for Locally Advanced Pancreatic Cancer (LAPC), employs a proprietary delivery system via RenovoTAMP. Upcoming plans include an interim analysis of the TIGeR-PaC study and investigations into extrahepatic Cholangiocarcinoma (eCCA).
RenovoRx (Nasdaq: RNXT) announced that its therapy platform, RenovoTAMP, was featured in two presentations at the Advanced Interventional Management Symposium. Dr. Ripal Gandhi discussed the potential of RenovoTAMP for treating locally advanced pancreatic cancer (LAPC), emphasizing a Phase III study, TIGeR-PaC, aimed at extending survival and reducing side effects. Dr. Christopher Laing explored RenovoTAMP's applications in pancreatic and bile duct cancers. The company aims to enhance chemotherapy delivery while minimizing toxicity, holding Orphan Drug Designation for its treatment approaches.
FAQ
What is the current stock price of RenovoRx (RNXT)?
What is the market cap of RenovoRx (RNXT)?
What does RenovoRx, Inc. specialize in?
What is the RenovoCath™ RC120?
What is the Trans-Arterial Micro-Perfusion (TAMP) platform?
Where is RenovoRx headquartered?
Who backs RenovoRx's initiatives?
What is the primary goal of RenovoRx's therapies?
How can I contact RenovoRx for more information?
What makes RenovoRx's technology unique?
Is RenovoRx currently in clinical stages?
What recent achievements has RenovoRx made?
